Sunday 18 October 2026
Export PALI’s income statement to Excel — free account
Palisade Bio, Inc.
PALI Healthcare Biotechnology
Palisade Bio, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $250,000.00. In the quarter to June 2026, revenue grew 19,900.0%, EPS grew 91.4% and free cash flow fell 318.4%, each against the same quarter a year earlier. Revenue growth for three consecutive years; insiders bought in the last twelve months.
1.41
0.13
−8.44%
Follow PALI
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
— | — | — | 3.23 |
P/S ratio |
— | — | — | 585.15 | |
P/FCF ratio |
— | — | — | 0.00 | |
P/Operating CF |
— | — | — | (58.11) | |
P/B ratio |
— | — | — | 3.63 | |
Price to Tangible BV |
— | — | — | 3.63 | |
EV/Sales |
— | — | — | 419.99 | |
EV/EBITDA |
— | — | — | 0.00 | |
EV/Operating CF |
— | — | — | (17.43) | |
EV/FCF |
— | — | — | (17.42) | |
Quick Ratio |
1.50 | 28.77 | 23.60 | 23.96 | |
Current Ratio |
1.96 | 28.95 | 23.71 | 24.26 | |
Net Debt/EBITDA |
1.72 | 13.33 | 12.34 | 10.70 | |
Debt/Assets |
3.03% | 0.29% | 0.00% | 0.00% | |
Debt/Equity |
0.07 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.01 | |
Operating CF/Net income |
1.24 | 0.35 | 0.41 | 0.72 | |
Capex/Depreciation |
0.00 | 0.00 | — | — | |
Interest Coverage |
(584.40) | (4,990.50) | (10,748.00) | — | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 1,480.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 959.60% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 957.00% | |
Graham Net Nets |
— | — | — | 0.28 | |
Graham Number |
— | — | — | 2.90 | |
Earnings Yield |
— | — | — | 30.99% | |
Free Cash Flow Yield |
— | — | — | (4.12%) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.48) | (0.06) | (0.02) | (0.04) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.48) | (0.06) | (0.02) | (0.04) | |
Cash per Share |
0.70 | 2.40 | 0.63 | 0.59 | |
Shareholders Equity per Share |
0.43 | 2.32 | 0.61 | 0.58 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.43 | 2.32 | 0.61 | 0.58 | |
Free Cash Flow |
(3.55) | (3.14) | (3.89) | (7.60) | |
Working Capital |
3.35 | 129.59 | 127.62 | 122.01 | |
Net Current Asset Value |
3.07 | 129.26 | 127.29 | 121.69 | |
EV/EBIT |
— | — | — | 0.00 | |
Capex to Sales |
— | — | — | 0.00 | |
Price to Operating Income |
— | — | — | 0.00 | |
| Other line items | |||||
Average Receivables |
— | — | — | 0.97 | |
Average Payables |
0.90 | 0.94 | 1.72 | 1.60 | |
Average Assets |
8.15 | 72.61 | 70.75 | 66.99 | |
Average Common Equity |
4.91 | 68.43 | 66.34 | 62.18 |
Columns are period end dates